Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer

  • 76 Accesses

  • 50 Citations

Abstract

Previous studies suggest a prognostic role for PDGF in patients with breast cancer, with patients with high plasma PDGF levels or positive response to therapy. We have examined a further 58 patients with advanced breast cancer for the presence of tissue PDGF immunostaining. Patients displaying positive tissue immunostaining for PDGF had a highly significant shorter survival (p = 0.002) than patients with no immunostaining. In addition PDGF positive patients treated with combination chemotherapy had a significantly lower response rate (p = 0.05) than PDGF negative patients. These results confirm our previous findings that PDGF may be an important indicator of shortened survival and treatment failure in patients with advanced breast cancer.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Ariad S, Seymour L, Bezwoda WR: Platelet derived growth factor (PDGF) in plasma of patients with breast cancer: correlation with stage and rate of progression. Breast Cancer Res Treat 20: 11–17, 1991

  2. 2.

    Seymour L, Dajee D, Bezwoda WR: Tissue platelet derived growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26: 247–252, 1993

  3. 3.

    Seymour L, Dajee D, Bezwoda WR: Tissue platelet derived growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26: 247–252, 1993

  4. 4.

    Seymour L, Meyer K, Esser J, MacPhail AP, Behr A, Bezwoda WR: Estimation of PR and ER by immunocytochemistry in breast cancer. Am J Clin Path 94: 35–40, 1990

  5. 5.

    Seymour L, Bezwoda WR, Meyer K: Tumour factors predicting for prognosis in metastatic breast cancer. Cancer 66: 2390–2394, 1990

  6. 6.

    Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292–298, 1977

  7. 7.

    Heidaran MA, Beeler JF, Yu J-C, Ishibashi T, LaRochelle WJ, Pierce JH, Aaronson SA: Differences in substrate specificities of α and β platelet derived growth factor (PDGF) receptors. J Biol Chem 268: 9287–9295, 1993

  8. 8.

    Fretto LJ, Snape AJ, Tomlinson JE, Seroogy JJ, Wolf DL, LaRochelle WJ, Giese NA: Mechanism of platelet derived growth factor (PDGF) AA, AB, and BB binding to α and β PDGF receptor. J Biol Chem 268: 3625–3631, 1993

  9. 9.

    Slamon DJ, DeKernion JB, Verma IM, Cline MJ: Expression of cellular oncogenes in human malignancies. Science 224: 256–259, 1984

  10. 10.

    Leal F, Williams L, Robbins K, Aaronson S: Evidence that the v-sis gene product transforms by interaction with the receptor for PDGF. Science 230: 327–330, 1985

  11. 11.

    Fleming TP, Matsui T, Heidaran MA, Molloy CJ, Artrip J, Aaronson SA: Demonstration of an activated Platelet Derived Growth Factor autocrine pathway and its role in human tumour cell proliferationin vitro. Oncogene 7: 1355–1359, 1992

  12. 12.

    Silver BJ: Platelet Derived Growth Factor in human malignancy. Biofactors 3: 217–227, 1992

  13. 13.

    Lokeshwar VB, Huang SS, Huang JS: Intracellular turnover, novel secretion, and mitogenically active intracellular forms of v-sis gene product in simian sarcoma virus-transformed cells. Implications for intracellular loop autocrine transformation. J Biol Chem 265: 1665–1675, 1990

  14. 14.

    Battegay EJ, Raines EW, Selfert RA, Bowen-Pope DF, Ross R: TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine loop. Cell 63: 515–524, 1990

  15. 15.

    Haberstroh U, Zahner G, Disser M, Thaiss F, Wolf G, Stahl RAK: TGF-β stimulated rat mesangial cell proliferation in culture role of PDGF β-receptor expression. Am J Physiol 264: F199-F205, 1993

  16. 16.

    Behl C, Bogdahn U, Winckler J, Apfel R, Brysch W, Schlingensiepen K-H: Autoinduction of Platelet Derived Growth Factor (PGDF) A chain mRNA expression in a human malignant melanoma cell line and growth inhibitory effects of PDGF-A chain mRNA-specific antisense molecules. Biochem Biophys Res Comm 193: 744–751, 1993

  17. 17.

    Van de Meeren A, Seddon MB, Betsholtz CA, Lechner JF, Gerwin BI: Tumorigenic conversion of human mesothelioma cells as a consequence of Platelet Derived Growth Factor A chain overexpression. Am J Respir Cell Mol Biol 8: 214–221, 1993

  18. 18.

    Langerak AW, Dirks RP, Versnel MA: Splicing of the Platelet Derived Growth Factor A chain mRNA in human malignant mesothelioma cell lines. Eur J Biochem 208: 589–596, 1992

  19. 19.

    Elliott B, Ostman A, Westermark B, Rubin K: Modulation of growth factor responsiveness of murine mammary carcinoma cells by cell matrix interactions: Correlation of cell proliferation and spreading. J Cell Physiol 152: 292–301, 1992

  20. 20.

    Taverna D, Groner B, Hynes NE: Epidermal Growth Factor Receptor, Platelet Derived Growth Factor Receptor and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation. Cell Growth Differ 2: 145–154, 1991

  21. 21.

    Bronzert DA, Bates SE, Sheridan JP, Lindsey R, Valverius EM, Stampfer MR, Lippman ME, Dickson RB: Transforming Growth Factor-β induces Platelet Derived Growth Factor (PDGF) messenger RNA and PDGF secretion while inhibiting growth in normal human mammary epithelial cells. Mol Endocrinol 4: 981–989, 1990

  22. 22.

    Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff K, Kasid A: Growth regulation of human breast cancer occurs through regulated growth factor secretion. J Cell Biochem 35: 1–16, 1987

  23. 23.

    Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB, Lippman ME: Synthesis and secretion of platelet derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci 84: 5763–5767, 1987

  24. 24.

    Rakowicz-Szulczynska EM, Koprowski H: Expression of A-type PDGF receptor in cytoplasm of tumor cell lines synthesising PDGF. Exp Mol Pathol 51: 171–178, 1989

  25. 25.

    Ginsburg E, Vonderhaar BK: Stimulation of growth of human breast cancer cells (T47D) by Platelet Derived Growth Factor. Cancer Lett 58: 137–144, 1991

  26. 26.

    Ariad S, Seymour L, Bezwoda WR: Platelet derived growth factor (PDGF) in plasma of patients with breast cancer: correlation with stage and rate of progression. Breast Cancer Res Treat 20: 11–17, 1991

  27. 27.

    Tingstrom A, Reuterdahl C, Lindahl P, Heldin C-H, Rubin K: Expression of Platelet Derived Growth Factor-β receptors on human fibroblasts. J Immunol 148: 546–554, 1992

  28. 28.

    Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG: Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1: 63–71, 1990

  29. 29.

    Funa K, Papanicolaou V, Juhlin C, Rastad J, Akerstrom G, Heldin C-H, Oberg K: Expression of Platelet Derived Growth Factor β-receptors on stromal tissue cells in human carcinoid cells. Cancer Res 50: 748–753, 1990

  30. 30.

    Bissell MJ, Hall HG, Parry G: How does the extracellular matrix direct gene expression? J Theor Biol 99: 31–68, 1982

  31. 31.

    Brooks RF, Howard M, Leake DS, Riddle PN: Failure of Platelet Derived Growth Factor plus insulin to stimulate sustained proliferation of Swiss 3T3 cells. Requirement for hydrocortisone, prostaglandin E, lipoproteins, fibronectin and an unidentified component derived from serum. J Cell Sci 97: 71–78, 1990

  32. 32.

    Golombick T, Dajee D, Bezwoda WR: Cell extracellular matrix interactions 2: Extracellular matrix structure is important for growth factor localisation and function. (In press)

Download references

Author information

Correspondence to W. R. Bezwoda.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Seymour, L., Bezwoda, W.R. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Tr 32, 229–233 (1994). https://doi.org/10.1007/BF00665774

Download citation

Key words

  • platelet derived growth factor
  • PDGF
  • breast cancer
  • immunohistochemistry
  • prognosis